Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Hematological Cancers Treatment: Oncology Pipeline with the Most Potential

By GBI Research | May 25, 2017

Hematological cancers pharmaceutical pipeline one of the strongest within oncology, says GBI Research.

The hematological cancers pipeline, which covers leukemia, lymphoma, and myeloma, is the largest within the oncology therapy area of pharmaceuticals, with 1,474 programs in active development and a total of 477 first-in-class pipeline programs, according to business intelligence provider GBI Research.

The company’s latest report states that cytokine signaling targets make up the greatest proportion of pipeline and first-in-class programs, followed in both instances by kinases. These two target categories are intrinsically linked with components of immune response, and are responsible for the majority of targets, in part due to the nature of hematological cancers and their action on immune cells. Additionally, much of the promising potential within the hematological cancers area revolves around targeted immunotherapies.

Callum Dew, Associate Analyst for GBI Research, explains: “As these disorders affect the immune cells within the blood and bone marrow, there is a high degree of pathophysiological crossover between the separate types of malignancy within hematological cancers, so it is not uncommon for products being developed for this therapy area to be tested across multiple indications. 214 first-in-class programs are being developed for a single indication, but 229 are in development for two or more hematological cancer indications, highlighting the versatility of current pipeline programs.”

With regard to individual molecular targets in the pipeline, 27.3 percent are first-in-class, which is a greater proportion than the industry average.

(Source: GBI Research)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50